- Tytuł:
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
- Autorzy:
- Źródło:
- Lancet Oncology. Oct2018, Vol. 19 Issue 10, p1315-1327. 13p.
Czasopismo naukowe